Qualcomm is preparing to fend off an unsolicited US$100 billion takeover bid from Broadcom Ltd, arguing it undervalues the company, people familiar with the plans said, according to the Financial Times.
Broadcom is preparing a US$70-a-share offer for Qualcomm, which could come as soon as Monday, November 6, said the people, who asked not to be identified because the plans are private.
Qualcomm will make the case to shareholders that, in addition to a possible battle with the board, Broadcom may also face challenges from regulators, the people said. Additionally, one of the Financial Times’ sources considers that as soon as the IP/antitrust battle with Apple is solved, Qualcomm’s stock will trade significantly higher than the US$70 offering.
While Qualcomm’s board and management will give the offer due consideration, the San Diego-based company will likely recommend that shareholders reject it, the people said. This would force Broadcom to pursue a proxy fight if it wishes to proceed.
A Qualcomm spokesman declined to comment, and Broadcom didn’t immediately respond to a request for comment.
Qualcomm will make the case to shareholders that, in addition to a possible battle with the board, Broadcom may also face challenges from regulators, the people said.
Broadcom has been trying since last year to secure approval for its purchase of Brocade Communications Systems Inc, a substantially smaller deal.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas